Benchmark analyst Bruce Jackson raised the firm’s price target on Humacyte (HUMA) to $17 from $15 and keeps a Buy rating on the shares. Humacyte announced it received full FDA approval for SYMVESS for use in adults as a a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and when autologous vein graft is not feasible, and the final labeling removes any reference to synthetic graft material, which is better than expected, the analyst tells investors in a research note. Benchmark continues to believe the company is poised to gain significant share for surgical procedures requiring vascular grafts, including reconstruction due to trauma, vascular access for dialysis patients, peripheral arterial disease repair, and, eventually, coronary artery bypass grafts and a BioVascular Pancreas.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. >;elm:context_link;itc:0;sec:content-canvas” class=”link “>Try Now>>
Read More on HUMA:
EMEA Tribune is not involved in this news article, it is taken from our partners and or from the News Agencies. Copyright and Credit go to the News Agencies, email news@emeatribune.com Follow our WhatsApp verified Channel
